The global market for Osteoporosis Therapeutics is projected to reach US$13.3 billion by 2025
NEW YORK, Oct. 21, 2020 /PRNewswire/ -- The global market for Osteoporosis Therapeutics is projected to reach US$13.3 billion by 2025, driven by rising awareness over the growing problem of osteoporosis and the ensuing emphasis on early diagnosis and treatment. With the percentage share of people aged 60 plus in the global population mix forecast to reach 21.5% from the current 12.7%, burden of osteoporosis will increase significantly accounting for over 75% of all fractures among the elderly. Although largely preventable, fractures result in long-term injuries, severe pain, long-term disability and high mortality. In the Europe, India, Japan and the United States over 150 million people live with osteoporosis, a number poised to rise significantly in the coming years. Medical emphasis on prevention and early diagnosis will therefore gain prominence providing the cornerstone for growth in the market. As losses in bone mineral density (BMD) is high in the elderly, aging population remains a key growth catalyst, with the risk of osteoporotic hip, vertebral and wrist fracture tripling with age. Economic burden of osteoporotic fractures (OFs) will grow bigger in sync with the aging population growth from 729.3 million people in the age group 65+ in 2020 to over 852.5 million by 2025. The cost of long-term disability from osteoporosis is huge since over 25% of elderly suffering from hip fracture will require permanent nursing home care. Also driving prevalence rates are factors such as rising incidence of vitamin D deficiencies, anorexia nervosa, growing cancer epidemic and increase in the number of patients undergoing chemotherapy and/or using glucocorticoids both of which tend to accelerate the loss of bone mineral density.
Read the full report: https://www.reportlinker.com/p05817617/?utm_source=PRN
The scenario offers a robust outlook for osteoporosis therapeutics. Osteoporosis therapeutics are mainly targeted at reducing the risk of fractures, and are categorized into two main drug categories, named antiresorptive or anabolic. Antiresorptive drugs reduce bone resorption and include mainly bisphosphonates, estrogens, estrogen agonist/ antagonists [EAAs], calcitonin, and denosumab. Anabolic drugs work by increasing bone formation and include teriparatide. Few of the approved drugs for osteoporosis include EVISTA (Selective Estrogen-Receptor Modulator (SERM); DUAVIVE (Estrogen and Selective Estrogen-Receptor Modulator (SERM); FORTEO (Parathyroid Hormone); ACLASTA/ACTONEL (Bisphosphonates); PROLIA (RANK ligand inhibitor); CLIMARA (Hormonal Therapy
Transdermal). Bisphosphonates represent the largest category of drugs for the treatment of osteoporosis and is recommended as the first line of treatment for the prevention of osteoporosis in postmenopausal women, men, and GIO patients. The market also stands to benefit from growing movement in the medical community over the need for further research for safe use of long-term osteoporosis drug therapies for fracture prevention. This will help attract funding support and will speed up the development of new treatments. The United States and Europe represent large markets worldwide with a combined share of 67.2% of the market. China ranks as the fastest growing market with a CAGR of 5.9% over the analysis period supported by attractive reimbursement policies. The national health system and private insurers together reimburse over 75% to 875% of inpatient osteoporosis treatments and 35% to 45% of outpatient care. Traditional Chinese medicine enjoys over is 80% reimbursement.
Read the full report: https://www.reportlinker.com/p05817617/?utm_source=PRN
I. INTRODUCTION, METHODOLOGY & REPORT SCOPE
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
A Prelude to Osteoporosis
Growing Geriatric Population and Rising Incidence of
Osteoporosis Drive the Global Osteoporosis Market
Developed Regions Dominate the Global Market, Developing to
Witness Fastest Growth
Bisphosphonates - The Largest Category of Drugs for Treating
Osteoporosis
Approved Drugs for Treatment of Osteoporosis
Select Recent Osteoporosis Drug Approvals
Global Competitor Market Shares
Osteoporosis Therapeutics Competitor Market Share Scenario
Worldwide by Leading Players (in %): 2018
Sales of Leading Osteoporosis Therapeutics: 2018
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Growing Incidence of Osteoporosis Augurs Well for Osteoporosis
Therapeutics
Global Osteoporosis Prevalence by Country/Region (2012 & 2022P):
Number of People with Osteoporosis in Millions for US, EU,
Japan, China and India
% of Women Affected by Osteoporosis
Osteoporosis - Factsheet
Osteoporosis in Men
Rising Geriatric Population and the Associated Bone Health
Issues to Drive Market Gains
Global Population of 65+ Individuals (In 000s) by Region for
the Years 2015, 2020 & 2025
Rising Prevalence of Osteoporosis in Post-menopausal Women
Propels Market Growth
Changing Lifestyle Impacting Bone Health
Recommended Daily Intake of Calcium and Vitamin D
Increasing Awareness Related to Osteoporosis Care
New Product Launches Foster Market Growth
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Osteoporosis
Therapeutics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027
Table 2: World Historic Review for Osteoporosis Therapeutics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019
Table 3: World 15-Year Perspective for Osteoporosis
Therapeutics by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets for
Years 2012, 2020 & 2027
Table 4: World Current & Future Analysis for Bisphosphonates by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027
Table 5: World Historic Review for Bisphosphonates by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019
Table 6: World 15-Year Perspective for Bisphosphonates by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027
Table 7: World Current & Future Analysis for Parathyroid
Hormone Therapy by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027
Table 8: World Historic Review for Parathyroid Hormone Therapy
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019
Table 9: World 15-Year Perspective for Parathyroid Hormone
Therapy by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027
Table 10: World Current & Future Analysis for Calcitonin by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027
Table 11: World Historic Review for Calcitonin by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019
Table 12: World 15-Year Perspective for Calcitonin by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027
Table 13: World Current & Future Analysis for Selective
Estrogen Inhibitors Modulator (SERM) by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2020 through 2027
Table 14: World Historic Review for Selective Estrogen
Inhibitors Modulator (SERM) by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019
Table 15: World 15-Year Perspective for Selective Estrogen
Inhibitors Modulator (SERM) by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2020 & 2027
Table 16: World Current & Future Analysis for Rank Ligand
Inhibitors by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027
Table 17: World Historic Review for Rank Ligand Inhibitors by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019
Table 18: World 15-Year Perspective for Rank Ligand Inhibitors
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027
Table 19: World Current & Future Analysis for Oral by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027
Table 20: World Historic Review for Oral by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019
Table 21: World 15-Year Perspective for Oral by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027
Table 22: World Current & Future Analysis for Injectables by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027
Table 23: World Historic Review for Injectables by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019
Table 24: World 15-Year Perspective for Injectables by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027
Table 25: World Current & Future Analysis for Other Routes of
Administration by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027
Table 26: World Historic Review for Other Routes of
Administration by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019
Table 27: World 15-Year Perspective for Other Routes of
Administration by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2020 & 2027
III. MARKET ANALYSIS
GEOGRAPHIC MARKET ANALYSIS
UNITED STATES
Table 28: USA Current & Future Analysis for Osteoporosis
Therapeutics by Drug Class - Bisphosphonates, Parathyroid
Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors
Modulator (SERM) and Rank Ligand Inhibitors - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027
Table 29: USA Historic Review for Osteoporosis Therapeutics by
Drug Class - Bisphosphonates, Parathyroid Hormone Therapy,
Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and
Rank Ligand Inhibitors Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019
Table 30: USA 15-Year Perspective for Osteoporosis Therapeutics
by Drug Class - Percentage Breakdown of Value Sales for
Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin,
Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand
Inhibitors for the Years 2012, 2020 & 2027
Table 31: USA Current & Future Analysis for Osteoporosis
Therapeutics by Route Of Administration - Oral, Injectables and
Other Routes of Administration - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027
Table 32: USA Historic Review for Osteoporosis Therapeutics by
Route Of Administration - Oral, Injectables and Other Routes of
Administration Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019
Table 33: USA 15-Year Perspective for Osteoporosis Therapeutics
by Route Of Administration - Percentage Breakdown of Value
Sales for Oral, Injectables and Other Routes of Administration
for the Years 2012, 2020 & 2027
CANADA
Table 34: Canada Current & Future Analysis for Osteoporosis
Therapeutics by Drug Class - Bisphosphonates, Parathyroid
Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors
Modulator (SERM) and Rank Ligand Inhibitors - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027
Table 35: Canada Historic Review for Osteoporosis Therapeutics
by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy,
Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and
Rank Ligand Inhibitors Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019
Table 36: Canada 15-Year Perspective for Osteoporosis
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Bisphosphonates, Parathyroid Hormone Therapy,
Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and
Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
Table 37: Canada Current & Future Analysis for Osteoporosis
Therapeutics by Route Of Administration - Oral, Injectables and
Other Routes of Administration - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027
Table 38: Canada Historic Review for Osteoporosis Therapeutics
by Route Of Administration - Oral, Injectables and Other Routes
of Administration Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019
Table 39: Canada 15-Year Perspective for Osteoporosis
Therapeutics by Route Of Administration - Percentage Breakdown
of Value Sales for Oral, Injectables and Other Routes of
Administration for the Years 2012, 2020 & 2027
JAPAN
Table 40: Japan Current & Future Analysis for Osteoporosis
Therapeutics by Drug Class - Bisphosphonates, Parathyroid
Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors
Modulator (SERM) and Rank Ligand Inhibitors - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027
Table 41: Japan Historic Review for Osteoporosis Therapeutics
by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy,
Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and
Rank Ligand Inhibitors Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019
Table 42: Japan 15-Year Perspective for Osteoporosis
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Bisphosphonates, Parathyroid Hormone Therapy,
Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and
Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
Table 43: Japan Current & Future Analysis for Osteoporosis
Therapeutics by Route Of Administration - Oral, Injectables and
Other Routes of Administration - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027
Table 44: Japan Historic Review for Osteoporosis Therapeutics
by Route Of Administration - Oral, Injectables and Other Routes
of Administration Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019
Table 45: Japan 15-Year Perspective for Osteoporosis
Therapeutics by Route Of Administration - Percentage Breakdown
of Value Sales for Oral, Injectables and Other Routes of
Administration for the Years 2012, 2020 & 2027
CHINA
Table 46: China Current & Future Analysis for Osteoporosis
Therapeutics by Drug Class - Bisphosphonates, Parathyroid
Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors
Modulator (SERM) and Rank Ligand Inhibitors - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027
Table 47: China Historic Review for Osteoporosis Therapeutics
by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy,
Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and
Rank Ligand Inhibitors Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019
Table 48: China 15-Year Perspective for Osteoporosis
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Bisphosphonates, Parathyroid Hormone Therapy,
Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and
Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
Table 49: China Current & Future Analysis for Osteoporosis
Therapeutics by Route Of Administration - Oral, Injectables and
Other Routes of Administration - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027
Table 50: China Historic Review for Osteoporosis Therapeutics
by Route Of Administration - Oral, Injectables and Other Routes
of Administration Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019
Table 51: China 15-Year Perspective for Osteoporosis
Therapeutics by Route Of Administration - Percentage Breakdown
of Value Sales for Oral, Injectables and Other Routes of
Administration for the Years 2012, 2020 & 2027
EUROPE
Table 52: Europe Current & Future Analysis for Osteoporosis
Therapeutics by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027
Table 53: Europe Historic Review for Osteoporosis Therapeutics
by Geographic Region - France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2019
Table 54: Europe 15-Year Perspective for Osteoporosis
Therapeutics by Geographic Region - Percentage Breakdown of
Value Sales for France, Germany, Italy, UK, Spain, Russia and
Rest of Europe Markets for Years 2012, 2020 & 2027
Table 55: Europe Current & Future Analysis for Osteoporosis
Therapeutics by Drug Class - Bisphosphonates, Parathyroid
Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors
Modulator (SERM) and Rank Ligand Inhibitors - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027
Table 56: Europe Historic Review for Osteoporosis Therapeutics
by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy,
Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and
Rank Ligand Inhibitors Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019
Table 57: Europe 15-Year Perspective for Osteoporosis
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Bisphosphonates, Parathyroid Hormone Therapy,
Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and
Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
Table 58: Europe Current & Future Analysis for Osteoporosis
Therapeutics by Route Of Administration - Oral, Injectables and
Other Routes of Administration - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027
Table 59: Europe Historic Review for Osteoporosis Therapeutics
by Route Of Administration - Oral, Injectables and Other Routes
of Administration Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019
Table 60: Europe 15-Year Perspective for Osteoporosis
Therapeutics by Route Of Administration - Percentage Breakdown
of Value Sales for Oral, Injectables and Other Routes of
Administration for the Years 2012, 2020 & 2027
FRANCE
Table 61: France Current & Future Analysis for Osteoporosis
Therapeutics by Drug Class - Bisphosphonates, Parathyroid
Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors
Modulator (SERM) and Rank Ligand Inhibitors - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027
Table 62: France Historic Review for Osteoporosis Therapeutics
by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy,
Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and
Rank Ligand Inhibitors Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019
Table 63: France 15-Year Perspective for Osteoporosis
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Bisphosphonates, Parathyroid Hormone Therapy,
Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and
Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
Table 64: France Current & Future Analysis for Osteoporosis
Therapeutics by Route Of Administration - Oral, Injectables and
Other Routes of Administration - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027
Table 65: France Historic Review for Osteoporosis Therapeutics
by Route Of Administration - Oral, Injectables and Other Routes
of Administration Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019
Table 66: France 15-Year Perspective for Osteoporosis
Therapeutics by Route Of Administration - Percentage Breakdown
of Value Sales for Oral, Injectables and Other Routes of
Administration for the Years 2012, 2020 & 2027
GERMANY
Table 67: Germany Current & Future Analysis for Osteoporosis
Therapeutics by Drug Class - Bisphosphonates, Parathyroid
Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors
Modulator (SERM) and Rank Ligand Inhibitors - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027
Table 68: Germany Historic Review for Osteoporosis Therapeutics
by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy,
Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and
Rank Ligand Inhibitors Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019
Table 69: Germany 15-Year Perspective for Osteoporosis
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Bisphosphonates, Parathyroid Hormone Therapy,
Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and
Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
Table 70: Germany Current & Future Analysis for Osteoporosis
Therapeutics by Route Of Administration - Oral, Injectables and
Other Routes of Administration - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027
Table 71: Germany Historic Review for Osteoporosis Therapeutics
by Route Of Administration - Oral, Injectables and Other Routes
of Administration Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019
Table 72: Germany 15-Year Perspective for Osteoporosis
Therapeutics by Route Of Administration - Percentage Breakdown
of Value Sales for Oral, Injectables and Other Routes of
Administration for the Years 2012, 2020 & 2027
ITALY
Table 73: Italy Current & Future Analysis for Osteoporosis
Therapeutics by Drug Class - Bisphosphonates, Parathyroid
Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors
Modulator (SERM) and Rank Ligand Inhibitors - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027
Table 74: Italy Historic Review for Osteoporosis Therapeutics
by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy,
Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and
Rank Ligand Inhibitors Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019
Table 75: Italy 15-Year Perspective for Osteoporosis
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Bisphosphonates, Parathyroid Hormone Therapy,
Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and
Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
Table 76: Italy Current & Future Analysis for Osteoporosis
Therapeutics by Route Of Administration - Oral, Injectables and
Other Routes of Administration - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027
Table 77: Italy Historic Review for Osteoporosis Therapeutics
by Route Of Administration - Oral, Injectables and Other Routes
of Administration Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019
Table 78: Italy 15-Year Perspective for Osteoporosis
Therapeutics by Route Of Administration - Percentage Breakdown
of Value Sales for Oral, Injectables and Other Routes of
Administration for the Years 2012, 2020 & 2027
UNITED KINGDOM
Table 79: UK Current & Future Analysis for Osteoporosis
Therapeutics by Drug Class - Bisphosphonates, Parathyroid
Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors
Modulator (SERM) and Rank Ligand Inhibitors - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027
Table 80: UK Historic Review for Osteoporosis Therapeutics by
Drug Class - Bisphosphonates, Parathyroid Hormone Therapy,
Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and
Rank Ligand Inhibitors Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019
Table 81: UK 15-Year Perspective for Osteoporosis Therapeutics
by Drug Class - Percentage Breakdown of Value Sales for
Bisphosphonates, Parathyroid Hormone Therapy, Calcitonin,
Selective Estrogen Inhibitors Modulator (SERM) and Rank Ligand
Inhibitors for the Years 2012, 2020 & 2027
Table 82: UK Current & Future Analysis for Osteoporosis
Therapeutics by Route Of Administration - Oral, Injectables and
Other Routes of Administration - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027
Table 83: UK Historic Review for Osteoporosis Therapeutics by
Route Of Administration - Oral, Injectables and Other Routes of
Administration Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019
Table 84: UK 15-Year Perspective for Osteoporosis Therapeutics
by Route Of Administration - Percentage Breakdown of Value
Sales for Oral, Injectables and Other Routes of Administration
for the Years 2012, 2020 & 2027
SPAIN
Table 85: Spain Current & Future Analysis for Osteoporosis
Therapeutics by Drug Class - Bisphosphonates, Parathyroid
Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors
Modulator (SERM) and Rank Ligand Inhibitors - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027
Table 86: Spain Historic Review for Osteoporosis Therapeutics
by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy,
Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and
Rank Ligand Inhibitors Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019
Table 87: Spain 15-Year Perspective for Osteoporosis
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Bisphosphonates, Parathyroid Hormone Therapy,
Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and
Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
Table 88: Spain Current & Future Analysis for Osteoporosis
Therapeutics by Route Of Administration - Oral, Injectables and
Other Routes of Administration - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027
Table 89: Spain Historic Review for Osteoporosis Therapeutics
by Route Of Administration - Oral, Injectables and Other Routes
of Administration Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019
Table 90: Spain 15-Year Perspective for Osteoporosis
Therapeutics by Route Of Administration - Percentage Breakdown
of Value Sales for Oral, Injectables and Other Routes of
Administration for the Years 2012, 2020 & 2027
RUSSIA
Table 91: Russia Current & Future Analysis for Osteoporosis
Therapeutics by Drug Class - Bisphosphonates, Parathyroid
Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors
Modulator (SERM) and Rank Ligand Inhibitors - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027
Table 92: Russia Historic Review for Osteoporosis Therapeutics
by Drug Class - Bisphosphonates, Parathyroid Hormone Therapy,
Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and
Rank Ligand Inhibitors Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019
Table 93: Russia 15-Year Perspective for Osteoporosis
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Bisphosphonates, Parathyroid Hormone Therapy,
Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and
Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
Table 94: Russia Current & Future Analysis for Osteoporosis
Therapeutics by Route Of Administration - Oral, Injectables and
Other Routes of Administration - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027
Table 95: Russia Historic Review for Osteoporosis Therapeutics
by Route Of Administration - Oral, Injectables and Other Routes
of Administration Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019
Table 96: Russia 15-Year Perspective for Osteoporosis
Therapeutics by Route Of Administration - Percentage Breakdown
of Value Sales for Oral, Injectables and Other Routes of
Administration for the Years 2012, 2020 & 2027
REST OF EUROPE
Table 97: Rest of Europe Current & Future Analysis for
Osteoporosis Therapeutics by Drug Class - Bisphosphonates,
Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen
Inhibitors Modulator (SERM) and Rank Ligand Inhibitors -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027
Table 98: Rest of Europe Historic Review for Osteoporosis
Therapeutics by Drug Class - Bisphosphonates, Parathyroid
Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors
Modulator (SERM) and Rank Ligand Inhibitors Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019
Table 99: Rest of Europe 15-Year Perspective for Osteoporosis
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Bisphosphonates, Parathyroid Hormone Therapy,
Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and
Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
Table 100: Rest of Europe Current & Future Analysis for
Osteoporosis Therapeutics by Route Of Administration - Oral,
Injectables and Other Routes of Administration - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027
Table 101: Rest of Europe Historic Review for Osteoporosis
Therapeutics by Route Of Administration - Oral, Injectables and
Other Routes of Administration Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019
Table 102: Rest of Europe 15-Year Perspective for Osteoporosis
Therapeutics by Route Of Administration - Percentage Breakdown
of Value Sales for Oral, Injectables and Other Routes of
Administration for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Table 103: Asia-Pacific Current & Future Analysis for
Osteoporosis Therapeutics by Geographic Region - Australia,
India, South Korea and Rest of Asia-Pacific Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027
Table 104: Asia-Pacific Historic Review for Osteoporosis
Therapeutics by Geographic Region - Australia, India, South
Korea and Rest of Asia-Pacific Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019
Table 105: Asia-Pacific 15-Year Perspective for Osteoporosis
Therapeutics by Geographic Region - Percentage Breakdown of
Value Sales for Australia, India, South Korea and Rest of
Asia-Pacific Markets for Years 2012, 2020 & 2027
Table 106: Asia-Pacific Current & Future Analysis for
Osteoporosis Therapeutics by Drug Class - Bisphosphonates,
Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen
Inhibitors Modulator (SERM) and Rank Ligand Inhibitors -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027
Table 107: Asia-Pacific Historic Review for Osteoporosis
Therapeutics by Drug Class - Bisphosphonates, Parathyroid
Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors
Modulator (SERM) and Rank Ligand Inhibitors Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019
Table 108: Asia-Pacific 15-Year Perspective for Osteoporosis
Therapeutics by Drug Class - Percentage Breakdown of Value
Sales for Bisphosphonates, Parathyroid Hormone Therapy,
Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and
Rank Ligand Inhibitors for the Years 2012, 2020 & 2027
Table 109: Asia-Pacific Current & Future Analysis for
Osteoporosis Therapeutics by Route Of Administration - Oral,
Injectables and Other Routes of Administration - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027
Table 110: Asia-Pacific Historic Review for Osteoporosis
Therapeutics by Route Of Administration - Oral, Injectables and
Other Routes of Administration Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019
Table 111: Asia-Pacific 15-Year Perspective for Osteoporosis
Therapeutics by Route Of Administration - Percentage Breakdown
of Value Sales for Oral, Injectables and Other Routes of
Administration for the Years 2012, 2020 & 2027
AUSTRALIA
Table 112: Australia Current & Future Analysis for Osteoporosis
Therapeutics by Drug Class - Bisphosphonates, Parathyroid
Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors
Modulator (SERM) and Rank Ligand Inhibitors - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027
Table 113: Australia Historic Review for Osteoporosis
Therapeutics by Drug Class - Bisphosphonates, Parathyroid
Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors
Modulator (SERM) and Rank Ligand Inhibitors Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019
Table 114: Australia 15-Year Perspective for Osteoporosis
Therapeutics by Drug Class - Percentage Breakdown of Value
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05817617/?utm_source=PRN
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article